Not recruitingEUCTR 2022-001151-16
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia
This historical record does not confirm current site availability.
Historical research recordBulgaria + Hungary
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
- Listed locations
- Pazardzhik and 17 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 850
- Sponsor
- Cerevel Therapeutics, LLC
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Bulgaria, Hungary
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2022-001151-16
- Official title
Show the full official title
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia
Recruitment & locations
Not recruitingPazardzhik, Bulgaria · Pleven, Bulgaria · Sliven, Bulgaria
9 more locations
- Sofia, Bulgaria
- Sofiya, Bulgaria
- Stara Zagora, Bulgaria
- Varna, Bulgaria
- Veliko Tirnovo, Bulgaria
- Vratsa, Bulgaria
- Budapest, Hungary
- Gyor, Hungary
- Kalocsa, Hungary
Registry details
Original registry record (opens in a new tab)A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Cerevel Therapeutics, LLC.
Who can participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as not recruiting.
Want to explore more studies?
Explore studiesRelated studies
2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai...